BackCelyad Oncology S.A. Overview

Celyad Oncology S.A. EBIT

Track Celyad Oncology S.A.'s EBIT ($-11M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$1.33M
↑ 64.08% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$11.30M
↓ 301.84% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Celyad Oncology S.A. (CLYYF) FAQ

The latest EBIT for CLYYF is $-11M as of June 2026. That compares with $5.6M in the prior-year period — down 301.8% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Celyad Oncology S.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, CLYYF's EBIT moved from $5.6M to $-11M — a 301.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Celyad Oncology S.A.'s operating scale or balance-sheet position.

Against Healthcare companies, CLYYF currently prints $-11M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Celyad Oncology S.A.'s growth, margins, and balance sheet.

A EBIT figure of $-11M for CLYYF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting CLYYF's EBIT ($-11M), review year-over-year change from $5.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.